Mikaela Naylon Give Kids a Chance Act

What happened?

Proposal in Congress

  1. Placed on the Union Calendar, Calendar No. 304.
  2. Mr. Carter (GA) moved to suspend the rules and pass the bill, as…
  3. Received in the Senate.

Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including…

Read the details

What this means

Status
Proposal in Congress
What happened
Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research. Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations t…
What to check next
See the latest action below for the next step in Congress.
Check the original record

About this record

Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research. Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research. The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)

Record details

Bill number
H.R. 1262
Congress
119
Introduced
2025-02-12
Sponsor
Rep. McCaul, Michael T. [R-TX-10]
Committees
Energy and Commerce Committee
Latest documented action
Received in the Senate.

Documented actions

  1. Received in the Senate.

  2. Motion to reconsider laid on the table Agreed to without objection.

  3. On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)

  4. Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4929-4932)

  5. DEBATE - The House proceeded with forty minutes of debate on H.R. 1262.

  6. Considered under suspension of the rules. (consideration: CR H4929-4935)

  7. Mr. Carter (GA) moved to suspend the rules and pass the bill, as amended.

  8. Placed on the Union Calendar, Calendar No. 304.

Sources and related records

Source checked .